ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apatinib

Also written as “Apatinib”, “Rivoceranib” and “Apatinib Mesylate”.

Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung, led by 8 companies.

Drug pageApatinib: every studyMany companies study it; this page follows only the 47 they lead. All 428 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jan 13, 201247 company-led studies, 8 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicineits history only344 open or runningphase 3since Jan 13, 2012Aug 30, 2010none ahead
Elevar Therapeutics70 open or runningphase 3since Jan 24, 2017Dec 18, 2011none ahead
Bukwang Pharmaceuticalits history only10 open or runningphase 1since Feb 26, 2016Feb 26, 2016none ahead
GrandPharma (China)its history only11 open or runningphase 2since Aug 13, 2025Aug 13, 2025Dec 30, 2027phase 2 · NCT07334483
Guangzhou Virotech Pharmaceuticalits history only11 open or runningphase 3since May 8, 2026May 8, 2026Dec 31, 2028phase 3 · NCT07589244
Hansoh Pharmaceutical Groupits history only11 open or runningphase 1since Jan 7, 2025Jan 7, 2025none ahead
HRYZ Biotechits history only11 open or runningearly phase 1since Aug 26, 2019Aug 26, 2019none ahead
Qilu Pharmaceuticalits history only10 open or runningphase 2since Aug 14, 2017Aug 14, 2017none ahead

Also a collaborator on its studies: Bukwang Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Elevar Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 18, 2011First study: phase 2 study in NeoplasmsFirst studyNCT01497704 · 55 enrolled · United States, Korea, Republic of
  2. Jan 24, 2017Phase 3 study in Stomach NeoplasmsNCT03042611 · 460 enrolled · United States, France, Germany and more
  3. Dec 21, 2017Phase 1 study in NeoplasmsNCT03396211 · 30 enrolled · United States
  4. Oct 8, 2018Phase 2 study in Stomach NeoplasmsNCT03707028 · 12 enrolled · Korea, Republic of
  5. Aug 26, 2019Phase 1 study in Colorectal NeoplasmsNCT04073615 · 29 enrolled · United States
  6. Sep 24, 2019Phase 2 study in Carcinoma, Adenoid CysticNCT04119453 · 80 enrolled · United States, South Korea
  7. Mar 10, 2022Phase 1 study in HealthyNCT05287360 · 60 enrolled · United States

TargetBeta

KDR →read by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
RamucirumabruleEli Lillyphase 358
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
vorolanibruleBetta Pharmaceuticalsphase 324
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleadvenchen-laboratories-nanjing-ltdphase 38
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37

Studies

All 7 Elevar Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05287360Healthy · United States1CompletedMar 16, 202260
NCT04119453Carcinoma, Adenoid Cystic · United States, South Korea2TerminatedJun 28, 202380
NCT04073615Colorectal Neoplasms · United States1TerminatedMay 31, 202329
NCT03707028Stomach Neoplasms · Korea, Republic of2TerminatedAug 24, 202112
NCT03396211Neoplasms · United States1CompletedOct 28, 202030
NCT03042611Stomach Neoplasms · United States, France, Germany and more3CompletedFeb 15, 2019460
NCT01497704Neoplasms · United States, Korea, Republic of2CompletedFeb 201555

How it is read

Names in the registry

  • “Apatinib”, 13 entries
  • “Rivoceranib”, 5 entries
  • “Apatinib Mesylate”, 5 entries
  • “apatinib”, 3 entries
  • “Fluzoparib+Apatinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.